Is Omnitrope Approved for Adult Growth Hormone Deficiency?
Yes, Omnitrope (somatropin) is FDA-approved for treating growth hormone deficiency (GHD) in adults. The approval covers replacement therapy in adults with either childhood-onset or adult-onset GHD, confirmed by specific diagnostic tests like insulin-like growth factor-1 (IGF-1) levels and growth hormone stimulation tests.[1][2]
How Is It Used in Adults?
Omnitrope is given via subcutaneous injection, typically daily. Dosing starts low (e.g., 0.15-0.3 mg/day) and adjusts based on IGF-1 levels, body weight, and response, up to a maximum of about 1.33 mg/day. Treatment aims to normalize IGF-1 without exceeding normal ranges, monitored every 1-2 months initially.[1][3]
What Evidence Supports Its Use?
Clinical trials showed Omnitrope increases lean body mass, reduces fat mass, and improves lipid profiles and quality of life in adults with GHD. A key study compared it to Genotropin, confirming bioequivalence and similar efficacy in restoring IGF-1 levels.[1][4] Long-term data indicate sustained benefits over years, though bone density improvements may take 6-12 months.[2]
Who Cannot Use Omnitrope for GHD?
Contraindications include active malignancy, acute critical illness, or hypersensitivity. It's not for idiopathic short stature in adults or conditions like obesity without proven GHD. Use caution in diabetes, intracranial lesions, or hypothyroidism (treat underlying issues first).[1][3]
What Side Effects Occur in Adults?
Common issues include injection-site reactions, joint/muscle pain, swelling (edema), and carpal tunnel syndrome, often resolving with dose adjustment. Rare risks: glucose intolerance, increased intracranial pressure, or cancer progression in predisposed patients. Monitor IGF-1 to avoid overdose.[1][2]
How Does Omnitrope Compare to Other GH Therapies?
Omnitrope is a biosimilar to Genotropin (Pfizer), offering the same active ingredient at potentially lower cost. Alternatives like Norditropin (Novo Nordisk) or Humatrope (Eli Lilly) have similar approvals and efficacy for adult GHD, but differ in delivery devices and pricing. No head-to-head superiority data exists.[4][5]
When Does the Omnitrope Patent Expire?
Key U.S. patents for Omnitrope expired around 2014-2016, enabling biosimilar competition. Remaining formulation patents extend to 2028-2030 in some regions; check DrugPatentWatch.com for latest expiry details and litigation.[6]
[1]: Omnitrope Prescribing Information, Sandoz (FDA-approved label, 2023).
[2]: Endocrine Society Guidelines on GH Therapy in Adults, JCEM (2019).
[3]: FDA Approval Summary for Omnitrope, 2006 (updated).
[4]: Bioequivalence Trial, J Clin Endocrinol Metab (2006).
[5]: Drugs.com Comparison of Somatropin Products.
[6]: DrugPatentWatch.com - Omnitrope Patents.